News >

Giant of Cancer Care Shares Insights on Adjuvant Therapy in Melanoma

Danielle Bucco
Published: Wednesday, Apr 18, 2018

John M. Kirkwood, MD

John M. Kirkwood, MD
Adjuvant treatment of patients with intermediate- and high-risk melanoma has changed drastically in the past decade, according to John M. Kirkwood, MD, whose pioneering work helped launch the first therapies in this disease setting more than 20 years ago.

“The goal we want to accomplish with adjuvant therapy in intermediate- and high-risk patients with melanoma is to reduce the risk of relapse [ie, improve relapse-free survival; RFS], improve overall survival [OS], and to provide a tolerable safety profile,” explained Kirkwood, who is the Usher Professor of Medicine, Dermatology & Translational Science at the University of Pittsburgh (UP) School of Medicine, and director of the Melanoma Center at the UP Medical Center’s Hillman Cancer Center. In 2017, he was named a Giants of Cancer Care® award winner in the melanoma category.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Community Practice Connections™: 15th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20202.0
Publication Bottom Border
Border Publication